Ropeginterferon alfa-2b improved responses overtime in patients with polycythemia vera who presented predominantly without splenomegaly compared with hydroxyurea, according to findings from the phase III PROUD-PV clinical trial and its extension study, CONTINUATION-PV.
Ropeginterferon alfa-2b improved responses overtime in patients with polycythemia vera (PV) who presented predominantly without splenomegaly compared with hydroxyurea, according to findings from the phase III PROUD-PV clinical trial and its extension study, CONTINUATION-PV. However, the primary end point of the study, non-inferiority to hydroxyurea, was not met.
Overall, 257 patients were assigned to either ropeginterferon alfa-2b (n = 127) or hydroxyurea (n = 127). A total of 171 patients also rolled over into the extension study. Median follow-up was 182.1 weeks for the experimental arm (range, 166.3-201.7) versus 164.5 weeks in the standard arm (range, 144.4-169.3).
Twenty-six patients out of 122 in the ropeginterferon alfa-2b arm (21%) met the composite primary end point of complete hematological response with normal spleen size at 12 months compared with 34 patients out of 123 (28%) in the standard arm (95% CI, -17.23-4.09;P=.23). Complete hematological responses were similar without the spleen criterion at 12 months in 53 patients (43%) in the ropeginterferon alfa-2b arm versus 57 patients (46%) in the hydroxyurea arm (95% CI, -15.55-9.52; P=.63).
In the ropeginterferon alfa-2b arm, a complete hematological response was observed in 18 of 46 patients who were pretreated with hydroxyurea (39%) compared with 35 of 77 patients who were not pretreated (46%; odds ratio, 0.57 [0.20-1.42]). In the standard arm, 15 of 47 patients who were previously treated (32%) and 42 of 78 patients who were not (54%) experienced a complete hematological response (odds ratio, 0.43 [0.17-1.02];P=.0666).
The proportion of patients with a complete hematological response in the CONTINUATION-PV study was significantly higher in the experimental arm. Complete hematological response with normalization of spleen size appeared to increase steadily over time in 27 of 91 patients (30%) at month 12 in the ropeginterferon alfa-2b arm compared with 38 of 90 patients (42%) at month 36. Investigators did not find a significant difference between the 2 arms, whereas at month 12, 33 of 76 patients (43%) and at month 36, 23 of 67 (34%) had complete hematological response with normalization of spleen size in the standard arm.
A larger proportion of patients maintained complete hematological response over the 36-month treatment period in the ropeginterferon alfa-2b arm (37 [39%] of 95) versus hydroxyurea arm (11 [15%] of 76;P= .0011). The experimental arm also had a larger proportion of patients who maintained complete hematological response with improved disease burden over the 36-month treatment period (28 [30%] of 95) compared with the standard arm (11 [15%] of 76;P= .025).
Molecular responses did not appear significantly different in the experimental arm (42 [34%] of 123) and the standard arm (52 [42%] of 123;P= 0.19).
Adverse events (AEs) that required dose reductions appeared in 51 of 127 patients (40%) in the ropeginterferon alfa-2b arm compared with 74 of 127 (58%) in the hydroxyurea arm, and dose interruptions were required in 29 of 127 (23%) versus 23 of 127 (18%) respectively. Overall, 11 (8%) patients in the ropeginterferon alfa-2b arm discontinued due to drug-related AEs, which included hypothyroidism (n = 2), dyspnea and pneumonitis, thrombocytopenia, increased aspartate aminotransferase and alanine aminotransferase, microcytic anemia and anemia, anxiety, psoriasis, depression, Sjogren’s syndrome, and rheumatoid arthritis (n =1 each). Five of 127 patients in the standard arm discontinued treatment due to AEs, which included thrombocytopenia and anemia, basal cell carcinoma, pyrexia, skin ulcer, and intolerance to hydroxyurea (n = 1 each).
The most common AEs in the experimental arm, occurring in less than 10% of patients, included thrombocytopenia (22%), leucopenia (20%), increased γ­glutamyltransferase (19%), fatigue (13%), increased alanine aminotransferase (13%), anemia (13%), increased aspartate aminotransferase (10%), headache (12%), arthralgia (12%), and dizziness (11%). In the standard arm, the most common AEs included thrombocytopenia (29%), anemia (25%), leucopenia (23%), fatigue (14%), headache (13%), nausea (12%), diarrhea (11%), and nasopharyngitis (10%).
There were 16 events in 13 of 127 (10%) patients in the experimental arm of major PV-related cardiovascular AEs compared with 25 events in 8 of 127 (6%) of patients in the standard arm. Investigators considered 2 of the events to be related to ropeginterferon alfa-2b, which included atrial fibrillation and intracardiac thrombus. One treatment-related death was observed in the standard arm.
Investigators noted that treatment-related AEs (TRAEs) occurred in 95 of 127 (75%) of patients in the ropeginterferon alfa-2b arm and 100 of 127 (79%) in the hydroxyurea arm. AEs of grade 3 or higher were similar between both treatment arms. Serious TRAEs occurred in 3 of 127 (2%) of patients in the experimental arm versus 5 of 127 (4%) in the standard arm.
In the randomized, controlled, open-label trial conducted in 48 clinics in Europe, patients were randomly assigned 1:1 to receive either ropeginterferon alfa-2b subcutaneously every 2 weeks at a starting dose of 100 μg or oral hydroxyurea starting at 500 mg/day. Patients could enter the extension portion of the study after 1 year.
Based on the durable hematological and molecular response and the tolerability observed with ropeginterferon alfa-2b in the PROUD-PV trial, Gisslinger et al concluded that the agent is a safe for long-term treatment of PV with features distinct fromhydroxyurea.
Reference:
Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study [Published Online January 31, 2020].Lancet. doi.org/10.1016/S2352-3026(19)30236-4.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More